Indian pharma company Lupin Limited has launched Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg in the US.

The product is the generic version of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development.

Invega (paliperidone), which is an atypical antipsychotic, which has approval in the US for the schizophrenia treatment in adults. It is also approved as a monotherapy for the treatment of schizoaffective disorder and as an adjunct for mood stabilizers and/or antidepressant therapy.

As per data from IQVIA MAT August 2022, Paliperidone Extended-Release Tablets had projected annual sales of $112 million in the US.

  Invega, Janssen Research and Development, Lupin, paliperidone, Schizophrenia, USA